Top 1% Biotech Reata Crashes On A Delay For Its Most Anticipated Drug
Reata Pharmaceuticals (RETA) scrapped a chronic kidney disease program and announced a delay for its first commercial product on Wednesday, and RETA stock plummeted. The Food and Drug Administration approved Reata’s Skyclarys for patients age […]